Community-acquired pneumonia (CAP) bears the risk of complications like severe sepsis or acute respiratory failure. A recent study has found different types of microRNA that may anticipate the development of those deteriorations and could easily be tested .
The prospective observational study, presented by Dr Francisco Sanz Herrero (University Hospital of Valencia, Spain), included 169 patients with CAP, aged between 58 and 79 years (mean age 66.9 years), all hospitalised in Valencia. A substantial proportion of them had important comorbidities like diabetes (29%), COPD (28.4%), arrhythmia (13.6%), and cerebrovascular disease (8.9%).
During the CAP treatment of these patients, 109 developed a complication. Acute hypoxic respiratory failure (AHRF) and severe sepsis were seen in 25.4% and 13.6% of the study subjects. Real-time PCR testing found a downregulation of microRNA-223 and microRNA-574 that had a high accuracy in predicting the onset of severe sepsis (area ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« COPD Patients Do Not Benefit from Azithromycin Therapy Longer than a Year Next Article
Balloon Pulmonary Angioplasty for Inoperable Chronic Thromboembolic Pulmonary Hypertension »
Table of Contents: ERS 2019
Holistic View on Asthma
Infectious Respiratory Disease: the Role of Vaccines
Interstitial Lung Disease
Best of the Posters
Novel Developments in Infectious Disease
A New Trial in Pulmonary Vascular Disease
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.